Lupin jumps after Q1 results

Lupin rose 4.84% to Rs 1,172.80 at 14:22 IST on BSE after consolidated net profit rose 55.77% to Rs 624.74 crore on 30.76% increase in total income to Rs 3369.73 crore in Q1 June 2014 over Q1 June 2013.

The company made the announcement during trading hours today, 30 July 2014.

Meanwhile, the BSE Sensex was up 38.78 points, or 0.15%, to 26,030.01.

On BSE, so far 2.81 lakh shares were traded in the counter, compared with an average volume of 58,816 shares in the past one quarter.

The stock hit a high of Rs 1,177 so far during the day, which is also a record high for the counter. The stock hit a low of Rs 1,113.20 so far during the day. The stock hit a 52-week low of Rs 742.30 on 28 August 2013.

The stock had outperformed the market over the past one month till 28 July 2014, rising 6.78% compared with 3.55% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, rising 11.95% as against Sensex's 14.84% rise.

The large-cap company has an equity capital of Rs 89.71 crore. Face value per share is Rs 2.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and cephalosporin segment. Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the third largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Powered by Capital Market - Live News